Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle

被引:23
作者
Löser, P
Hillgenberg, M
Arnold, W
Both, GW
Hofmann, C
机构
[1] HepaVec AG Gentherapie, D-13125 Berlin, Germany
[2] CSIRO, Div Mol Sci, N Ryde, NSW 2113, Australia
关键词
ovine adenovirus vectors; skeletal muscle; pre-existing antibodies; human alpha(1)-antitrypsin; readministration;
D O I
10.1038/sj.gt.3301260
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ovine adenovirus (OAV) vectors represent a promising fool for human gene therapy since these vectors overcome the problem of pre-existing immunity against human adenovirus vectors. in this report we investigated the in vivo characteristics of this novel vector system with respect to its potential for gene transfer into skeletal muscle. We found that moderate doses of an OAV-derived vector expressing the human alpha(1)-antitrypsin gene (OAVhaat) infected skeletal muscle in mice very efficiently resulting in high serum hAAT levels. The infection was restricted to skeletal muscle, but gene expression was transient and vector DNA was rapidly cleared. Vector clearance was also observed with a vector that lacked the transgene. The loss of vector DNA was accompanied by a cellular immune response in the infected muscle but was not connected with detectable expression of early or late genes of the viral backbone as analyzed by RT-PCR. A very low dose of OAVhaat (3 x 10(7) infectious particles) was sufficient to produce reasonable amounts (> 100 ng/ml) of serum hAAT, and this was accompanied by a weak immune response to the vector. Under these conditions, a second intramuscular injection of the same recombinant OAV vector was successful. Our study expands the known tissue tropism of OAV-derived vectors in vivo and points to the possible utility of the vector for muscle gene transfer and vaccination.
引用
收藏
页码:1491 / 1498
页数:8
相关论文
共 50 条
[1]   A DIFFERENTIAL EFFICIENCY OF ADENOVIRUS-MEDIATED IN-VIVO GENE-TRANSFER INTO SKELETAL-MUSCLE CELLS OF DIFFERENT MATURITY [J].
ACSADI, G ;
JANI, A ;
MASSIE, B ;
SIMONEAU, M ;
HOLLAND, P ;
BLASCHUK, K ;
KARPATI, G .
HUMAN MOLECULAR GENETICS, 1994, 3 (04) :579-584
[2]  
ACSADI G, 1994, GENE THER, V1, P338
[3]  
BARR D, 1995, GENE THER, V2, P151
[4]   SYSTEMIC DELIVERY OF RECOMBINANT PROTEINS BY GENETICALLY MODIFIED MYOBLASTS [J].
BARR, E ;
LEIDEN, JM .
SCIENCE, 1991, 254 (5037) :1507-1509
[5]   CHARACTERIZATION OF AUSTRALIAN OVINE ADENOVIRUS ISOLATES [J].
BOYLE, DB ;
PYE, AD ;
KOCHERHANS, R ;
ADAIR, BM ;
VRATI, S ;
BOTH, GW .
VETERINARY MICROBIOLOGY, 1994, 41 (03) :281-291
[6]   Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates [J].
Brann, T ;
Kayda, D ;
Lyons, RM ;
Shirley, P ;
Roy, S ;
Kaleko, M ;
Smith, T .
HUMAN GENE THERAPY, 1999, 10 (18) :2999-3011
[7]   Persistence in muscle of an adenoviral vector that lacks all viral genes [J].
Chen, HH ;
Mack, LM ;
Kelly, R ;
Ontell, M ;
Kochanek, S ;
Clemens, PR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) :1645-1650
[8]   Immune responses to adenovirus and adeno-associated virus in humans [J].
Chirmule, N ;
Propert, KJ ;
Magosin, SA ;
Qian, Y ;
Qian, R ;
Wilson, JM .
GENE THERAPY, 1999, 6 (09) :1574-1583
[9]   Transient immunosuppression with 15-deoxyspergualin prolongs reporter gene expression and reduces humoral immune response after adenoviral gene transfer [J].
Cichon, G ;
Strauss, M .
GENE THERAPY, 1998, 5 (01) :85-90
[10]  
Clemens PR, 1996, GENE THER, V3, P965